Autolus Therapeutics plc

Contributing Author

Recent Articles by Autolus Therapeutics plc

Jan-12	Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 AUTL GlobeNewswire
Jan-06	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform AUTL GlobeNewswire
Dec-08	Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Dec-08	Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Dec-01	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors AUTL GlobeNewswire
Nov-25	NICE Recommends AUCATZYL (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ AUTL GlobeNewswire
Nov-13	Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London AUTL GlobeNewswire
Nov-12	Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire
Nov-03	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Oct-30	Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 AUTL GlobeNewswire
Oct-27	Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 AUTL GlobeNewswire
Oct-20	Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis AUTL GlobeNewswire
Oct-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Sep-16	Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 AUTL GlobeNewswire
Aug-12	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire
Jul-24	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 AUTL GlobeNewswire
Jul-21	Autolus Therapeutics' CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
Jul-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Jun-12	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-29	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL GlobeNewswire
May-23	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
May-14	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-08	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire

Autolus Therapeutics plc

Recent Articles by Autolus Therapeutics plc

Upgrade your FINVIZ experience